TrialStem cells translational medicine2026

Five-year follow-up of phase II trial of autologous cord blood mononuclear cells for bronchopulmonary dysplasia prevention in very preterm infants.

Zhuxiao Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.